<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-112229" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Undifferentiated Pleomorphic Sarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Robles-Tenorio</surname>
            <given-names>Arturo</given-names>
          </name>
          <aff>Universidad de Guadalajara</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Solis-Ledesma</surname>
            <given-names>Guillermo</given-names>
          </name>
          <aff>Instituto Dermatologico de Jalisco "Dr. Jose Barba Rubio"</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arturo Robles-Tenorio declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Guillermo Solis-Ledesma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-112229.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The undifferentiated pleomorphic sarcoma (UPS), formerly known as malignant fibrous histiocytoma (MFH), is a high-grade soft-tissue sarcoma (STS). The historical literature previously encompassed various STSs as MFH. These were later reclassified as distinct entities, with the advancements in cytogenetics and immunohistochemistry studies. This activity reviews the current description, evaluation, and management of UPS and highlights the interprofessional team's role in improving the care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of undifferentiated pleomorphic sarcoma.</p></list-item><list-item><p>Describe the evaluation protocol for undifferentiated pleomorphic sarcoma.</p></list-item><list-item><p>Outline treatment alternatives for undifferentiated pleomorphic sarcoma according to disease staging.</p></list-item><list-item><p>Review how interprofessional strategies can optimize patient outcomes in cases of undifferentiated pleomorphic sarcoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=112229&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=112229">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-112229.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The undifferentiated pleomorphic sarcoma (UPS) &#x02014;formerly known as malignant fibrous histiocytoma, is a high-grade aggressive&#x000a0;soft-tissue sarcoma (STS). Mesenchymal stem cells are the most likely origin of the tumor, instead of histiocytes as previously thought.<xref ref-type="bibr" rid="article-112229.r1">[1]</xref>&#x000a0;It can affect soft tissues, bones, retroperitoneum, and metastasize to several organs. The earliest reports suggested it was the most common soft-tissue sarcoma (STS) in the adult population.<xref ref-type="bibr" rid="article-112229.r2">[2]</xref>&#x000a0;Subsequent analyses employing immunohistochemistry markers and sophisticated cytogenetics demonstrated that many of those tumors corresponded to other types of sarcomas.<xref ref-type="bibr" rid="article-112229.r3">[3]</xref><xref ref-type="bibr" rid="article-112229.r4">[4]</xref>&#x000a0;</p>
        <p>Prior subclassifications of MFH into storiform, pleomorphic, myxoid, giant cell, and angiomatoid variants are now rarely utilized. The definition of this tumor has been a matter of debate for more than five decades. Hence, a significant limitation of the historical literature is that only the most recent studies can confidently characterize this entity. At present, UPS is diagnosed by excluding other well-classified STSs.<xref ref-type="bibr" rid="article-112229.r1">[1]</xref></p>
      </sec>
      <sec id="article-112229.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact pathogenic mechanisms of UPS remain obscure. In general, STSs are composed of heterogeneous populations of cells with mesenchymal features that can originate from simple genomic alterations or complex genomics.<xref ref-type="bibr" rid="article-112229.r5">[5]</xref>&#x000a0;UPS belongs to the latter group, showcasing various potential cellular backgrounds, mutational signatures, and altered signaling pathways.</p>
        <p>The tumorigenesis of UPS is reportedly initiated by a subpopulation of cells called side population (SP) cells, which the Hoechst dye efflux assay can identify. According to an elegant xenograft experimental model, these cells have an increased capacity for self-renewal, growth, proliferation and can recapitulate tumor formation. UPS-derived SP cells and UPS in situ analyses showed that Hedgehog and Notch signaling pathways and downstream transcriptional targets are notoriously upregulated at both subcellular and tissue levels.<xref ref-type="bibr" rid="article-112229.r6">[6]</xref></p>
        <p>The Hippo pathway may also be implicated in UPS tumor biology, as vestigial-like family member 3 (VGLL3) and yes1-associated transcriptional regulator (YAP1) cofactors were found to be highly amplified on a genome sequencing study.<xref ref-type="bibr" rid="article-112229.r7">[7]</xref>&#x000a0;In various other reports, there are well-documented loss or deletion mutations of phosphatase and tensin homolog (PTEN) and overexpression of phosphorylated protein kinase B (pAKT) in UPS, involved in the PIK3/PTEN/AKT/mTOR pathway.<xref ref-type="bibr" rid="article-112229.r8">[8]</xref></p>
        <p>Similarly, Dickkopf-related protein 1 (DKK1), a Wnt/B-catenin signaling pathway inhibitor, was differentially overexpressed in UPS compared to other STSs.<xref ref-type="bibr" rid="article-112229.r9">[9]</xref>&#x000a0;In the same publication, hierarchical cluster analysis of stem cell genes showed a significant correlation between human mesenchymal stem cells (hMSC) and UPS genetic signature; and also confirmed that Dkk1 was necessary for hMSC differentiation.</p>
        <p>Mutations in tumor protein 53 (TP53), cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoblastoma-associated protein (RB1), and transcriptional regulator ATRX (ATRX) genes, as well as PR domain zinc finger protein 10 (PRDM10)&#x000a0;and triple functional domain protein (TRIO)&#x000a0;gene fusions have also been identified in UPS.<xref ref-type="bibr" rid="article-112229.r10">[10]</xref><xref ref-type="bibr" rid="article-112229.r11">[11]</xref><xref ref-type="bibr" rid="article-112229.r12">[12]</xref><xref ref-type="bibr" rid="article-112229.r13">[13]</xref><xref ref-type="bibr" rid="article-112229.r14">[14]</xref></p>
        <p>Besides genetic aberrations, radiation therapy (RT) is a known risk factor for STS development. Indeed, radiation-associated STS presents in around 1% to 3% of subjects diagnosed with any sarcoma. Specifically, in a series of 1068 UPS cases, 5.1% of the patients had a prior history of radiation.<xref ref-type="bibr" rid="article-112229.r15">[15]</xref></p>
      </sec>
      <sec id="article-112229.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The 2020 World Health Organization classification of STSs incorporates UPS under malignant tumors of uncertain differentiation.<xref ref-type="bibr" rid="article-112229.r16">[16]</xref>&#x000a0;According to the Surveillance, Epidemiology and End Results (SEER) program, UPS accounted for 17.1% out of 26,758 cases and was the second most common STS after leiomyosarcoma, regardless of the primary tumor site. Males showed considerably increased incidence rates than females, and white males were more commonly affected than black males. Incidence also linearly increased with advanced age, which was higher beyond the 6th decade of life.<xref ref-type="bibr" rid="article-112229.r17">[17]</xref></p>
      </sec>
      <sec id="article-112229.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology examination is essential for the diagnosis of UPS.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref>&#x000a0;The core needle technique is preferred over open incisional biopsy for initial evaluation. An experienced surgeon should perform the latter, considering the future resection incision, minimizing dissection and hemorrhage risk. Fine-needle aspiration is not recommended, mainly due to insufficient sampling. Should the diagnosis be unattainable with the first biopsy specimen, an image-guided core needle biopsy is encouraged. Endoscopic needle biopsy ought to be considered for deep thoracic, abdominal or pelvic tumors.</p>
        <p>On light microscopy, UPS exhibits atypical, pleomorphic spindle cells with abundant mitotic figures. Depth of invasion&#x000a0;can extend through the deep dermis, hypodermis, fascia, and striated muscle. The tumor may display a storiform, fascicular, or sheet-like configuration&#x000a0;within a fibrous stroma.<xref ref-type="bibr" rid="article-112229.r19">[19]</xref>&#x000a0;The National Comprehensive Cancer Network (NCCN) guideline defines deep tumors by the superficial fascia and beyond.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref>&#x000a0;Precisely distinguishing between superficial versus deep UPS may only serve may be a prognostic indicator.<xref ref-type="bibr" rid="article-112229.r20">[20]</xref>&#x000a0;Nonetheless, visualization of deep-tissue invasion and lack of solar elastosis in UPS is useful to&#x000a0;discard atypical fibroxanthoma.<xref ref-type="bibr" rid="article-112229.r21">[21]</xref><xref ref-type="bibr" rid="article-112229.r22">[22]</xref></p>
        <p>The definitive diagnosis of UPS is confirmed by excluding other malignancies with a panel of immunohistochemical markers.<xref ref-type="bibr" rid="article-112229.r22">[22]</xref>&#x000a0;These should include keratins, S100 protein and/or SOX10; smooth muscle actin (SMA); and desmin, expressed in metastatic sarcomatoid carcinoma, melanoma, and pleomorphic myogenic sarcomas, respectively. For internal, intrathoracic, or intraabdominal tumors, MDM2 and CDK4 help dismiss the possibility of dedifferentiated liposarcoma. A recent study demonstrated that LN2, CD10, and ezrin markers were similarly expressed in UPS and atypical fibroxanthoma, in contrast with earlier reports suggesting that LN2 had a high sensitivity for UPS.<xref ref-type="bibr" rid="article-112229.r23">[23]</xref>&#x000a0;Vimentin, p53, and Ki67 are other reportedly expressed IHC markers in UPS, although these are&#x000a0;clearly&#x000a0;not disease-specific.<xref ref-type="bibr" rid="article-112229.r21">[21]</xref><xref ref-type="bibr" rid="article-112229.r24">[24]</xref><xref ref-type="bibr" rid="article-112229.r25">[25]</xref><xref ref-type="bibr" rid="article-112229.r26">[26]</xref></p>
        <p>A complete post-operative histopathology report must mention the location of the tumor, depth of invasion, size, histologic grade, presence or absence of necrosis, excision margins status, vascular involvement, mitotic rate, type and extension of the inflammatory infiltrate, as well as the tumor, node, and metastasis (TNM) staging.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref></p>
      </sec>
      <sec id="article-112229.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>UPS typically appears as an asymptomatic, unremarkable, rapidly growing cutaneous or subcutaneous nodule without superficial skin abnormalities.<xref ref-type="bibr" rid="article-112229.r21">[21]</xref>&#x000a0;Internal, intrathoracic, and intraabdominal UPS may show mass effect&#x000a0;and/or constitutional symptoms.<xref ref-type="bibr" rid="article-112229.r27">[27]</xref><xref ref-type="bibr" rid="article-112229.r28">[28]</xref><xref ref-type="bibr" rid="article-112229.r29">[29]</xref>&#x000a0;In a recent retrospective analysis of 100 UPS cases, the extremities were the most commonly involved location (55%), followed by the trunk (35%), retroperitoneum (9%), and the left atrium (1%).<xref ref-type="bibr" rid="article-112229.r30">[30]</xref>&#x000a0;In another series of 266 cases, the average tumor size was 8.8&#x000a0;+/- 6.6 cm.<xref ref-type="bibr" rid="article-112229.r31">[31]</xref>&#x000a0;In radiation-associated UPS, the median latency time between radiation and tumor development was 9.33&#x000a0;+/- 1.31 years.<xref ref-type="bibr" rid="article-112229.r15">[15]</xref></p>
      </sec>
      <sec id="article-112229.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Once the diagnosis has been confirmed&#x000a0;with histopathology and immunohistochemistry, evaluation and workup include imaging of the primary tumor, lymph nodes, and distant metastases. The TNM staging criteria will vary depending on the location of the tumor. The NCCN guideline Version 1.2021 recommends performing magnetic resonance imaging (MRI) with contrast to determine tumor size, invasion of visceral structures, and neurovascular involvement.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref>&#x000a0;</p>
        <p>Chest, abdominal, and pelvic non-contrast computed tomography (CT) should be considered when internal viscera or retroperitoneal involvement is suspected. Total spine, head, and neck MRI or CT may be requested in particular cases. There is not enough evidence to recommend sentinel lymph node biopsy (SLNB) or positron emission tomography (PET) in UPS. Yet, it is worth noting that a recent systematic review and meta-analysis concluded that (18)F-fluorodeoxyglucose PET scan is a useful predictive tool in patients with STSs and bone sarcomas.<xref ref-type="bibr" rid="article-112229.r32">[32]</xref>&#x000a0;Furthermore, since molecular diagnosis has not been formally established for UPS, research efforts should focus on this matter for further characterization, prognostic, and therapeutic purposes.<xref ref-type="bibr" rid="article-112229.r1">[1]</xref></p>
      </sec>
      <sec id="article-112229.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The standard of care for head, neck, trunk, and extremities UPS is en bloc surgical excision with microscopically negative margins, particularly for stage I tumors. This may be achieved by wide local excision with 2 cm margins of uninvolved tissue, albeit some cases may pose greater difficulty due to the involvement of important neurovascular structures. Postoperative radiotherapy (RT) is indicated when margins are close to the tumor (&#x0003c; 1 cm), microscopically positive, involve bone, major blood vessels, or nerves.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref><xref ref-type="bibr" rid="article-112229.r19">[19]</xref> Effective RT should cover a 5 cm margin&#x000a0;and&#x000a0;can be administered through external beam RT (EBRT) (50 Gy), intraoperative RT (IORT) (10-16 Gy), low-dose brachytherapy (LDR) (45 Gy), or its high-dose equivalent (HDR).<xref ref-type="bibr" rid="article-112229.r18">[18]</xref><xref ref-type="bibr" rid="article-112229.r21">[21]</xref>&#x000a0;In a retrospective study of 266 patients, subjects treated with inadequate margins (marginal or intralesional) had a 1.82 higher death rate than those who received wide margin excision.<xref ref-type="bibr" rid="article-112229.r31">[31]</xref>&#x000a0;Moreover, adjuvant RT reduced mortality and metastatic disease in 68% and 66% of UPS patients, respectively. In the past, Mohs micrographic surgery (MMS) has also been utilized when trying to preserve healthy tissue.<xref ref-type="bibr" rid="article-112229.r33">[33]</xref><xref ref-type="bibr" rid="article-112229.r34">[34]</xref>&#x000a0;Extremity amputation is the last alternative since overall survival rates were not superior to limb-sparing surgery.<xref ref-type="bibr" rid="article-112229.r35">[35]</xref></p>
        <p>Broadly, chemotherapy with different antineoplastics is employed for advanced, widespread, or irresectable stages of various STSs.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref>&#x000a0;Stages II and III should involve multidisciplinary action to discuss the appropriateness of pre- or postoperative chemoradiation. Unresectable cases can be approached with chemotherapy, chemoradiation, or regional limb therapy. For stage IV patients, there is insufficient data to support a specific plan, and expert oncologists in STSs must be consulted. In a comparative study including 286 patients, histotype-tailored neoadjuvant chemotherapy was not superior to standard chemotherapy (epirubicin plus ifosfamide) in patients with high-risk STSs. Indeed, disease-free survival was superior in UPS-affected subjects receiving standard chemotherapy (HR 2.17, 95% CI, 0.98 &#x02013; 4.80) than those treated with the histotype-specific regime (gemcitabine plus docetaxel).<xref ref-type="bibr" rid="article-112229.r36">[36]</xref>&#x000a0;This was also confirmed in a wider, open-label, randomized, controlled study that included 435 STS patients from&#x000a0;four countries, confirming that anthracycline plus ifosfamide must remain the preferred treatment.<xref ref-type="bibr" rid="article-112229.r37">[37]</xref>&#x000a0;Beyond traditional chemotherapy for UPS, immune-checkpoint inhibition with pembrolizumab (anti-PD1), nivolumab (anti-PD1), and ipilimumab (anti-CTLA4) is currently under investigation.<xref ref-type="bibr" rid="article-112229.r38">[38]</xref><xref ref-type="bibr" rid="article-112229.r39">[39]</xref></p>
        <p>Similar&#x000a0;principles apply to internal, retroperitoneal, or intraabdominal UPS management. Excision with negative margins, with or without IORT, is the treatment of choice for resectable disease, whilst chemotherapy, chemoradiation, or HDR are preferred for unresectable cases.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref></p>
      </sec>
      <sec id="article-112229.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The most common differential diagnoses of UPS are other types of STSs, which must be distinguished by clinical history, physical examination, and immunohistochemistry markers.<xref ref-type="bibr" rid="article-112229.r19">[19]</xref><xref ref-type="bibr" rid="article-112229.r3">[3]</xref>&#x000a0;These include atypical fibroxanthoma, liposarcoma, leiomyosarcoma, liposarcoma, angiosarcoma, fibrosarcoma, myxofibrosarcoma, dermatofibrosarcoma protuberans, osteosarcoma, and malignant peripheral nerve sheath tumor. Metastases, desmoplastic melanoma, and spindle-cell squamous cell carcinoma may also resemble UPS clinical or histopathological morphology.<xref ref-type="bibr" rid="article-112229.r21">[21]</xref></p>
      </sec>
      <sec id="article-112229.s10" sec-type="Staging">
        <title>Staging</title>
        <p>Trunk and extremities UPS is staged according to the TNM and histologic grade (G) (Table 1).<xref ref-type="bibr" rid="article-112229.r18">[18]</xref><xref ref-type="bibr" rid="article-112229.r40">[40]</xref>&#x000a0;G&#x000a0;is defined by the differentiation, mitotic count, and necrosis extension of the tumor, as stated by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) (Table 2). After TNM and G evaluation, the disease is classified into stages I-IV for therapeutic purposes (Table 3).</p>
        <table-wrap id="article-112229.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. TNM and G Criteria</title>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">T: Primary Tumor</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Tx</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Primary tumor cannot be assessed</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>T0</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>No evidence of primary tumor</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>T1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Tumor &#x02264; 5 cm in greatest dimension</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>T2</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Tumor &#x0003e; 10 cm and &#x02264; 15 cm</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>T4 </bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Tumor &#x0003e; 15 cm in greatest dimension</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">N: Regional Lymph Nodes</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>N0</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>No regional lymph node metastasis or unknown lymph node status</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>N1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Regional lymph node met&#x000e1;stasis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">M: Distant metastasis</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>M0</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>No distant met&#x000e1;stasis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>M1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Distant met&#x000e1;stasis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">G: Histologic grade</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>GX</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Grade cannot be assessed</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>G1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Total differentiation, mitotic count, and necrosis score 2 or 3</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>G2</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Total differentiation, mitotic count, and necrosis score 4 or 5</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>G3</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Total differentiation, mitotic count, and necrosis score 6, 7, or 8</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-112229.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Histologic Grade</title>
          </caption>
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Histologic grade</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>The sum of differentiation, mitotic activity, and extent of necrosis scores. &#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Tumor differentiation</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Closely resembling normal adult mesenchymal tissue.</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>2</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Certain histologic typing</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>3</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Embryonal, synovial, Ewing, primitive neuroectodermal, and undifferentiated sarcoma</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Mitotic activity</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>0-9 mitoses per 10 high power field</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>2</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>10-19 mitoses per 10 high power field</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>3</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>&#x02265; 20 mitoses per 10 high power field</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold><italic toggle="yes">Tumor necrosis</italic></bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>0</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>No necrosis</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>1</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>&#x0003c; 50% necrosis</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>2</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>&#x02265; 50% necrosis</p>
</td>
                <td rowspan="1" colspan="1">
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>&#x000a0;Table 3. Tumor Staging &#x000a0;</bold>
</p>
        <table-wrap id="article-112229.table2" position="float" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Stage</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>T</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>N</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>M</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>G</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>IA</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T1</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G1, GX</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>IB</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T2</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G1, GX</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T3</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G1, GX</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T4</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G1, GX</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>II</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T1</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G2, G3</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>IIIA</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T2</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G2, G3</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>IIIB</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T3</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G2, G3</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>T4</p>
</td>
                <td rowspan="1" colspan="1">
<p>N0</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>G2, G3</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Any T</p>
</td>
                <td rowspan="1" colspan="1">
<p>N1</p>
</td>
                <td rowspan="1" colspan="1">
<p>M0</p>
</td>
                <td rowspan="1" colspan="1">
<p>Any G</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>IV</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Any T</p>
</td>
                <td rowspan="1" colspan="1">
<p>Any N</p>
</td>
                <td rowspan="1" colspan="1">
<p>M1</p>
</td>
                <td rowspan="1" colspan="1">
<p>Any G</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Staging of head, neck, abdominal, thoracic, and retroperitoneum tumors can be consulted on the American Joint Committee on Cancer Staging (AJCC) Manual 8th Edition, 2017.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref></p>
      </sec>
      <sec id="article-112229.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Early disease recognition and an adequate treatment strategy are the most important interventions to improve overall prognosis. In a current retrospective study of 319 patients from three tertiary care centers, recurrences and metastases occurred in 14.1% and 7.8% of the cases, respectively.<xref ref-type="bibr" rid="article-112229.r41">[41]</xref>&#x000a0;The recurrence risk was significantly increased with preoperative tumors greater than 5 cm, invasion beyond the subcutaneous fat, and advanced AJCC staging. Besides these, metastasis risk was also significantly increased in 2-5 cm tumors and those with lymphatic or vascular invasion. However, an important limitation of this work is that atypical fibroxanthoma diagnoses were pooled together with UPS. In a UPS-specific report, post-treatment local recurrence (15%) was statistically associated with advanced age and inadequate surgical margins, whilst post-treatment metastatic disease (37.6%) was significantly relevant in tumors &#x02265; 5 cm.<xref ref-type="bibr" rid="article-112229.r31">[31]</xref>&#x000a0;</p>
        <p>The 5- and 10-year overall survival rates were 60% and 48%, respectively. Interestingly, in another publication, the 5-year disease-specific survival and recurrence rates were significantly worse in radiation-associated UPS than sporadic UPS, suggesting there might be distinct mutational profiles for the disease.<xref ref-type="bibr" rid="article-112229.r15">[15]</xref></p>
        <p>Follow-up visits are important to detect local recurrences or metastasis. Physical examination of stage I tumors should be performed at 3-to-6-month intervals for the first two years and then annually.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref>&#x000a0;Imaging studies are not generally indicated unless prompted by clinical signs and symptoms. Stage II to IV disease must be followed every 2-to-6 months for 2 to 3 years, then every 6 months for 2 years, and annually thereafter. Post-operative MRI with and without contrast or contrast CT are recommended for primary tumor site assessment. Subsequent imaging of the affected and distant areas may be warranted based on the individual risk of recurrence.</p>
      </sec>
      <sec id="article-112229.s12" sec-type="Complications">
        <title>Complications</title>
        <p>As with many other high-grade STSs, the most common complications include local recurrences, metastasis, and death. Depending on the affected area, these may also be treatment-related, presenting as disability due to limb amputation, organ damage sequalae, wound complications, and neurovascular compromise.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref><xref ref-type="bibr" rid="article-112229.r42">[42]</xref><xref ref-type="bibr" rid="article-112229.r43">[43]</xref></p>
      </sec>
      <sec id="article-112229.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education about UPS is vital for reassurance, adherence to treatment, and follow-up. A study showed that up to 45% of newly diagnosed sarcoma patients show signs of psychological distress.<xref ref-type="bibr" rid="article-112229.r44">[44]</xref>&#x000a0;The impact on daily life activities and finances, lack of information resources, the need for group support, and healthcare system bureaucracy ranked amongst the top concerns in these patients.<xref ref-type="bibr" rid="article-112229.r45">[45]</xref></p>
      </sec>
      <sec id="article-112229.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Per the current guideline recommendations, an interprofessional healthcare team should be involved in the treatment decisions.<xref ref-type="bibr" rid="article-112229.r18">[18]</xref>&#x000a0;This usually involves surgical (general, plastic, reconstructive, vascular, orthopedic) and medical (oncology, radiation oncology) specialists with extensive experience in STSs. [Level 5] However, it is worth noting that general practitioners will first see the majority of the patients, and some will proceed to physiotherapy and occupational therapy after specialist treatment.<xref ref-type="bibr" rid="article-112229.r46">[46]</xref>&#x000a0;Therefore, first-care providers and non-specialists training courses can also improve overall patient care. [Level 5] Nursing and pharmacy will also contribute each from their areas of expertise. Lastly, community-level education is essential to increase disease awareness and facilitate the establishment and diffusion of sarcoma organizations and support groups.<xref ref-type="bibr" rid="article-112229.r45">[45]</xref>&#x000a0;This interprofessional approach to care will yield the best possible patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-112229.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=112229&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=112229">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/undifferentiated-pleomorphic-sarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=112229">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/112229/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=112229">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-112229.s16">
        <fig id="article-112229.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Undifferentiated pleomorphic sarcoma. Panoramic view shows an ill-defined dermal neoplasm extending to adipose tissue. Contributed by Juan Gabriel Garcia-Barrientos, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-112229.s17">
        <fig id="article-112229.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Undifferentiated pleomorphic sarcoma. Bundles of atypical neoplastic cells arranged in a storiform pattern. Contributed by Juan Gabriel Garcia-Barrientos, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-112229.s18">
        <fig id="article-112229.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Undifferentiated Pleomorphic Sarcoma. Pleomorphic cells with abundant atypical mitoses. Contributed by Juan Gabriel Garcia-Barrientos, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="8" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-112229.s19">
        <title>References</title>
        <ref id="article-112229.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldblum</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>An approach to pleomorphic sarcomas: can we subclassify, and does it matter?</article-title>
            <source>Mod Pathol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>27 Suppl 1</volume>
            <fpage>S39</fpage>
            <page-range>S39-46</page-range>
            <pub-id pub-id-type="pmid">24384852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Enzinger</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Malignant fibrous histiocytoma: an analysis of 200 cases.</article-title>
            <source>Cancer</source>
            <year>1978</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>2250</fpage>
            <page-range>2250-66</page-range>
            <pub-id pub-id-type="pmid">207408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hornick</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?</article-title>
            <source>Mod Pathol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>Suppl 1</issue>
            <fpage>56</fpage>
            <page-range>56-65</page-range>
            <pub-id pub-id-type="pmid">31653978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelleher</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Viterbo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma".</article-title>
            <source>Cancers (Basel)</source>
            <year>2013</year>
            <month>Feb</month>
            <day>22</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>218</fpage>
            <page-range>218-33</page-range>
            <pub-id pub-id-type="pmid">24216705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Widemann</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Italiano</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>10</day>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-167</page-range>
            <pub-id pub-id-type="pmid">29220302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghanbari-Azarnier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whetstone</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wunder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Alman</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas.</article-title>
            <source>Cancer Res</source>
            <year>2012</year>
            <month>Feb</month>
            <day>15</day>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>1013</fpage>
            <page-range>1013-22</page-range>
            <pub-id pub-id-type="pmid">22232736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e9;lias-Rodzewicz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chibon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lagarde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Aurias</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas.</article-title>
            <source>Genes Chromosomes Cancer</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>12</issue>
            <fpage>1161</fpage>
            <page-range>1161-71</page-range>
            <pub-id pub-id-type="pmid">20842732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stefano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giovanni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2019</year>
            <month>Aug</month>
            <day>14</day>
            <volume>11</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">31416195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matushansky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hernando</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Socci</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Edgar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Cordon-Cardo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway.</article-title>
            <source>J Clin Invest</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>117</volume>
            <issue>11</issue>
            <fpage>3248</fpage>
            <page-range>3248-57</page-range>
            <pub-id pub-id-type="pmid">17948129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chibon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lagarde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Th&#x000e9;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ranch&#x000e8;re</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Aurias</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.</article-title>
            <source>Am J Pathol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>177</volume>
            <issue>4</issue>
            <fpage>2080</fpage>
            <page-range>2080-90</page-range>
            <pub-id pub-id-type="pmid">20884963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simons</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schepens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeuken</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sprenger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van de Zande</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bjerkehagen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Forus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weibolt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molenaar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Myklebost</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Kessel</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Suijkerbuijk</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma.</article-title>
            <source>Cancer Genet Cytogenet</source>
            <year>2000</year>
            <month>Apr</month>
            <day>15</day>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-98</page-range>
            <pub-id pub-id-type="pmid">10748288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.</article-title>
            <source>Cancer Genomics Proteomics</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-228</page-range>
            <pub-id pub-id-type="pmid">31018952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofvander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tayebwa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brosj&#x000f6;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vult von Steyern</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mandahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma.</article-title>
            <source>Clin Cancer Res</source>
            <year>2015</year>
            <month>Feb</month>
            <day>15</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>864</fpage>
            <page-range>864-9</page-range>
            <pub-id pub-id-type="pmid">25516889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delespaul</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lesluyes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brulard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lartigue</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lagarde</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Le Guellec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neuville</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vince-Ranch&#x000e8;re</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Debant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chibon</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recurrent TRIO Fusion in Nontranslocation-Related Sarcomas.</article-title>
            <source>Clin Cancer Res</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>857</fpage>
            <page-range>857-867</page-range>
            <pub-id pub-id-type="pmid">27528700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dineen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Roland</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demicco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sannaa</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Ravi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guadagnolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cormier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>3913</fpage>
            <page-range>3913-20</page-range>
            <pub-id pub-id-type="pmid">25743327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-58</page-range>
            <pub-id pub-id-type="pmid">32960834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toro</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases.</article-title>
            <source>Int J Cancer</source>
            <year>2006</year>
            <month>Dec</month>
            <day>15</day>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>2922</fpage>
            <page-range>2922-30</page-range>
            <pub-id pub-id-type="pmid">17013893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Mehren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ganjoo</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Heslin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Homsi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keedy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liebner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McCarter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGarry</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Parkes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Paz</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Poppe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schuetze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shabason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sicklick</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Spraker</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Zimel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2020</year>
            <month>Dec</month>
            <day>02</day>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>1604</fpage>
            <page-range>1604-1612</page-range>
            <pub-id pub-id-type="pmid">33285515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nascimento</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Raut</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults.</article-title>
            <source>J Surg Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <day>15</day>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>330</fpage>
            <page-range>330-9</page-range>
            <pub-id pub-id-type="pmid">18286476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rydholm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gustafson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Should tumor depth be included in prognostication of soft tissue sarcoma?</article-title>
            <source>BMC Cancer</source>
            <year>2003</year>
            <month>May</month>
            <day>26</day>
            <volume>3</volume>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">12769830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henderson</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hollmig</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Malignant fibrous histiocytoma: changing perceptions and management challenges.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1335</fpage>
            <page-range>1335-41</page-range>
            <pub-id pub-id-type="pmid">22677489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hornick</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Subclassification of pleomorphic sarcomas: How and why should we care?</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>37</volume>
            <fpage>118</fpage>
            <page-range>118-124</page-range>
            <pub-id pub-id-type="pmid">30340082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moynes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.</article-title>
            <source>Cancer</source>
            <year>1997</year>
            <month>Jun</month>
            <day>01</day>
            <volume>79</volume>
            <issue>11</issue>
            <fpage>2115</fpage>
            <page-range>2115-24</page-range>
            <pub-id pub-id-type="pmid">9179057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leader</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Vimentin: an evaluation of its role as a tumour marker.</article-title>
            <source>Histopathology</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-72</page-range>
            <pub-id pub-id-type="pmid">2435649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roland</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Al Sannaa</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Dineen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Landers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Guadagnolo</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cormier</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>2220</fpage>
            <page-range>2220-8</page-range>
            <pub-id pub-id-type="pmid">26847678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanlon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stasko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cyrus</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.</article-title>
            <source>Dermatol Surg</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>431</fpage>
            <page-range>431-436</page-range>
            <pub-id pub-id-type="pmid">28079637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Povar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Horndler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arazo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Portoles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Velilla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Malignant fibrous histiocytoma of soft tissue: description of 10 cases].</article-title>
            <source>Med Clin (Barc)</source>
            <year>1991</year>
            <month>Jan</month>
            <day>12</day>
            <volume>96</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-10</page-range>
            <pub-id pub-id-type="pmid">1850813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawarabayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wakami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshihara</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Taki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishiwaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tane</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Primary cardiac malignant fibrous histiocytoma with abdominal wall metastasis.</article-title>
            <source>J Cardiol Cases</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>139</fpage>
            <page-range>139-142</page-range>
            <pub-id pub-id-type="pmid">30546578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salem</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shamseddine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khalife</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nounou</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>El Naaj</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mukherji</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haydar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faraj</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Malignant fibrous histiocytoma presenting with complete opacification of the hemithorax: A case report.</article-title>
            <source>Int J Surg Case Rep</source>
            <year>2014</year>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>1162</fpage>
            <page-range>1162-3</page-range>
            <pub-id pub-id-type="pmid">25437664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Undifferentiated Pleomorphic Sarcoma: Long-Term Follow-Up from a Large Institution.</article-title>
            <source>Cancer Manag Res</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>10001</fpage>
            <page-range>10001-10009</page-range>
            <pub-id pub-id-type="pmid">31819633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vodanovich</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Spelman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choong</surname>
                <given-names>PFM</given-names>
              </name>
            </person-group>
            <article-title>Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.</article-title>
            <source>ANZ J Surg</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>89</volume>
            <issue>9</issue>
            <fpage>1045</fpage>
            <page-range>1045-1050</page-range>
            <pub-id pub-id-type="pmid">31364245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Furuta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Johan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Ochi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.</article-title>
            <source>Eur J Cancer</source>
            <year>2016</year>
            <month>May</month>
            <volume>58</volume>
            <fpage>104</fpage>
            <page-range>104-11</page-range>
            <pub-id pub-id-type="pmid">26990930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of malignant fibrous histiocytoma and atypical fibrous xanthomas with micrographic surgery.</article-title>
            <source>J Dermatol Surg Oncol</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>1287</fpage>
            <page-range>1287-92</page-range>
            <pub-id pub-id-type="pmid">2556464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huether</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zitelli</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brodland</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Mohs micrographic surgery for the treatment of spindle cell tumors of the skin.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>656</fpage>
            <page-range>656-9</page-range>
            <pub-id pub-id-type="pmid">11260542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glatstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeMoss</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Seipp</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sindelar</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Sugarbaker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wesley</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.</article-title>
            <source>Ann Surg</source>
            <year>1982</year>
            <month>Sep</month>
            <volume>196</volume>
            <issue>3</issue>
            <fpage>305</fpage>
            <page-range>305-15</page-range>
            <pub-id pub-id-type="pmid">7114936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quagliuolo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Broto</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pousa</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Tendero</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Beveridge</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ferraresi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lugowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Merlo</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marchesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Palassini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Sanctis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morosi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bagu&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruzzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>812</fpage>
            <page-range>812-822</page-range>
            <pub-id pub-id-type="pmid">28499583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Quagliuolo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Martin Broto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lopez Pousa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brunello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Tendero</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Diaz Beveridge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferraresi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lugowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Merlo</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marchesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Braglia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Palassini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morosi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bagu&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruzzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>38</volume>
            <issue>19</issue>
            <fpage>2178</fpage>
            <page-range>2178-2186</page-range>
            <pub-id pub-id-type="pmid">32421444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keung</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Cormier</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ashleigh Guadagnolo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>VO</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wargo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Somaiah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roland</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.</article-title>
            <source>BMC Cancer</source>
            <year>2018</year>
            <month>Sep</month>
            <day>24</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>913</fpage>
            <pub-id pub-id-type="pmid">30249211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wisdom</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mowery</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Kirsch</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.</article-title>
            <source>Cancer</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>124</volume>
            <issue>19</issue>
            <fpage>3819</fpage>
            <page-range>3819-3829</page-range>
            <pub-id pub-id-type="pmid">29723407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cates</surname>
                <given-names>JMM</given-names>
              </name>
            </person-group>
            <article-title>The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-152</page-range>
            <pub-id pub-id-type="pmid">29439175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winchester</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tello</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chimato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hocker</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Markey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yom</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mully</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Otley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arron</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>853</fpage>
            <page-range>853-859</page-range>
            <pub-id pub-id-type="pmid">29787841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abouarab</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Degheidy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Henn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hirche</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eweida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uhl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kneser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic options and postoperative wound complications after extremity soft tissue sarcoma resection and postoperative external beam radiotherapy.</article-title>
            <source>Int Wound J</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <page-range>148-158</page-range>
            <pub-id pub-id-type="pmid">29205902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elswick</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Curiel</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Akhavan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Molinar</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Martinez-Jorge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saint-Cyr</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Complications after thigh sarcoma resection.</article-title>
            <source>J Surg Oncol</source>
            <year>2020</year>
            <month>May</month>
            <volume>121</volume>
            <issue>6</issue>
            <fpage>945</fpage>
            <page-range>945-951</page-range>
            <pub-id pub-id-type="pmid">32020627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srikanthan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shokoohi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smrke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience.</article-title>
            <source>Sarcoma</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>5302639</fpage>
            <pub-id pub-id-type="pmid">31354383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weaver</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sobhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carey Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Halkett</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The unmet needs of patients with sarcoma.</article-title>
            <source>Psychooncology</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>1209</fpage>
            <page-range>1209-1216</page-range>
            <pub-id pub-id-type="pmid">32419264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-112229.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Rehabilitation Strategies and Outcomes of the Sarcoma Patient.</article-title>
            <source>Phys Med Rehabil Clin N Am</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>171</fpage>
            <page-range>171-180</page-range>
            <pub-id pub-id-type="pmid">27912995</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
